BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT)

Equities research analysts at BTIG Research started coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $41.00 price target on the biotechnology company’s stock. BTIG Research’s target price would indicate a potential upside of 149.54% from the company’s current price.

Other analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Arcturus Therapeutics has a consensus rating of “Buy” and a consensus target price of $61.60.

Arcturus Therapeutics Trading Down 4.0 %

ARCT opened at $16.43 on Tuesday. The firm has a market capitalization of $445.04 million, a PE ratio of -7.40 and a beta of 2.63. The firm’s 50-day moving average price is $17.28 and its 200 day moving average price is $19.66. Arcturus Therapeutics has a twelve month low of $14.30 and a twelve month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. During the same quarter in the previous year, the company posted ($0.61) EPS. As a group, analysts predict that Arcturus Therapeutics will post -2.31 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new stake in Arcturus Therapeutics during the second quarter worth approximately $718,000. Millennium Management LLC lifted its position in Arcturus Therapeutics by 250.1% in the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after acquiring an additional 396,505 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Arcturus Therapeutics in the second quarter valued at $142,000. SG Americas Securities LLC purchased a new position in shares of Arcturus Therapeutics during the third quarter worth about $191,000. Finally, nVerses Capital LLC acquired a new stake in shares of Arcturus Therapeutics during the third quarter worth about $42,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.